107 related articles for article (PubMed ID: 8186369)
1. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.
Lu ZY; Brailly H; Rossi JF; Wijdenes J; Bataille R; Klein B
Cytokine; 1993 Nov; 5(6):578-82. PubMed ID: 8186369
[TBL] [Abstract][Full Text] [Related]
2. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY; Brailly H; Wijdenes J; Bataille R; Rossi JF; Klein B
Blood; 1995 Oct; 86(8):3123-31. PubMed ID: 7579407
[TBL] [Abstract][Full Text] [Related]
3. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.
Lu ZY; Brochier J; Wijdenes J; Brailly H; Bataille R; Klein B
Eur J Immunol; 1992 Nov; 22(11):2819-24. PubMed ID: 1425909
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting IL-6 in human multiple myeloma.
Klein B; Lu ZY; Gaillard JP; Harousseau JL; Bataille R
Curr Top Microbiol Immunol; 1992; 182():237-44. PubMed ID: 1490360
[No Abstract] [Full Text] [Related]
5. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.
Rossi JF; Fegueux N; Lu ZY; Legouffe E; Exbrayat C; Bozonnat MC; Navarro R; Lopez E; Quittet P; Daures JP; Rouillé V; Kanouni T; Widjenes J; Klein B
Bone Marrow Transplant; 2005 Nov; 36(9):771-9. PubMed ID: 16113665
[TBL] [Abstract][Full Text] [Related]
6. Polyvalent immunoglobulin significantly attenuated the formation of IL-1β in Escherichia coli-induced sepsis in pigs.
Barratt-Due A; Sokolov A; Gustavsen A; Hellerud BC; Egge K; Pischke SE; Lindstad JK; Pharo A; Castellheim A; Thorgersen EB; Mollnes TE
Immunobiology; 2013 May; 218(5):683-9. PubMed ID: 22947599
[TBL] [Abstract][Full Text] [Related]
7. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia.
Derhaschnig U; Bergmair D; Marsik C; Schlifke I; Wijdenes J; Jilma B
Crit Care Med; 2004 May; 32(5):1136-40. PubMed ID: 15190963
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulating IL-6 activity by murine monoclonal antibodies.
Brochier J; Legouffe E; Liautard J; Gaillard JP; Mao LQ; Bataille R; Rossi JF; Klein B
Int J Immunopharmacol; 1995 Jan; 17(1):41-8. PubMed ID: 7782152
[TBL] [Abstract][Full Text] [Related]
9. Proinflammatory cytokines increase in sepsis after anti-adhesion molecule therapy.
Welty-Wolf KE; Carraway MS; Ghio A; Kantrow SP; Huang YC; Piantadosi CA
Shock; 2000 May; 13(5):404-9. PubMed ID: 10807017
[TBL] [Abstract][Full Text] [Related]
10. Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-alpha.
Jansen PM; de Jong IW; Hart M; Kim KJ; Aarden LA; Hinshaw LB; Taylor FB; Hack CE
J Immunol; 1996 Jun; 156(11):4401-7. PubMed ID: 8666813
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF treatment of baboons with sepsis reduces TNF-alpha, IL-6 and IL-8, but not the degree of complement activation.
Bengtsson A; Redl H; Schlag G; Högåsen K; Götze O; Mollnes TE
Scand J Immunol; 1998 Nov; 48(5):509-14. PubMed ID: 9822260
[TBL] [Abstract][Full Text] [Related]
12. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
van Zaanen HC; Koopmans RP; Aarden LA; Rensink HJ; Stouthard JM; Warnaar SO; Lokhorst HM; van Oers MH
J Clin Invest; 1996 Sep; 98(6):1441-8. PubMed ID: 8823310
[TBL] [Abstract][Full Text] [Related]
13. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
14. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.
van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; van der Lelie J; van Oers MH
Br J Haematol; 1998 Aug; 102(3):783-90. PubMed ID: 9722307
[TBL] [Abstract][Full Text] [Related]
15. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
[TBL] [Abstract][Full Text] [Related]
16. Procalcitonin release patterns in a baboon model of trauma and sepsis: relationship to cytokines and neopterin.
Redl H; Schlag G; Tögel E; Assicot M; Bohuon C
Crit Care Med; 2000 Nov; 28(11):3659-63. PubMed ID: 11098970
[TBL] [Abstract][Full Text] [Related]
17. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.
Legouffe E; Liautard J; Gaillard JP; Rossi JF; Wijdenes J; Bataille R; Klein B; Brochier J
Clin Exp Immunol; 1994 Nov; 98(2):323-9. PubMed ID: 7955540
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma presenting high fever and high serum levels of lactic dehydrogenase, CRP, and interleukin-6.
Murakami H; Takada S; Hatsumi N; Yokohama A; Saitoh T; Uchiumi H; Maehara T; Matsushima T; Tsukamoto N; Morita K; Tamura J; Sawamura M; Karasawa M
Am J Hematol; 2000 May; 64(1):76-7. PubMed ID: 10815794
[TBL] [Abstract][Full Text] [Related]
19. Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes.
Martens E; Dillen C; Put W; Heremans H; van Damme J; Billiau A
Eur J Immunol; 1993 Aug; 23(8):2026-9. PubMed ID: 8344369
[TBL] [Abstract][Full Text] [Related]
20. Effects of antimurine interleukin-6 on bacterial translocation during gut-derived sepsis.
Gennari R; Alexander JW; Pyles T; Hartmann S; Ogle CK
Arch Surg; 1994 Nov; 129(11):1191-7. PubMed ID: 7979952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
